



**THE FOUNDATION
FOR SECURE
MARKETS**

#47150

DATE: JUNE 17, 2020

SUBJECT: FBRX1 OPTIONS - EXPIRATION PRICING CONSIDERATION

FBRX1 (adjusted Forte Biosciences, Inc. options) will be subject to special pricing consideration in expiration processing on June 19, 2020. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of FBRX1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

FBRX1

FBRX1 options are adjusted Forte Biosciences, Inc. (formerly Tocagen Inc.) options, adjusted June 16, 2020 (see OCC Information Memo #47136). The deliverable of FBRX1 options is:

NEW DELIVERABLE

PER CONTRACT: 1) 6 Forte Biosciences, Inc. (FBRX) Common Shares
 2) Cash in lieu of approximately 0.6667 fractional FBRX Shares

As of June 17, 2020, the FBRX Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating an FBRX1 price for use in expiration processing, OCC will use the following formula:

$$\text{FBRX1} = 0.066667 (\text{FBRX})$$

For example, if FBRX closes at 16.80, the FBRX1 price would be:

$$\text{FBRX1} = 0.066667 (16.80) = 1.12$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.